Abstract:BackgroundStimulator of interferon genes (STING) has emerged as a crucial and promising target in tumor immunotherapy in recent years. Its agonists play a vital role in activating both innate and adaptive immune responses to combat cancer. Currently, STING agonists are primarily administered through intratumoral or intravenous injection, with only a few could be administered by orally. Therefore, orally available STING agonists are urgently needed to be developed.Approach and resultsBased on previous structure-activity relationship (SAR) studies, we made a structure modification to MSA-2 by replacing the carbonyl group with a difluoromethylene to get a new compound 202 (C202) that exhibited better plasma exposure and oral bioavailability than MSA-2. Thus, we conducted extensive pharmacological evaluations to understand its effects. C202 demonstrated the ability to activate various human STING isoforms and murine STING protein, showcasing a potent and specific activation of the STING signalling pathway at cellular level. In diverse immunocompetent mouse models representing both 'cold' and 'hot' tumors, C202, whether administered intratumorally or orally, displayed broad-spectrum anti-tumor activity. Encouragingly, it induced complete tumor regression in several tumor models of mice and stimulated immune memory effects, contributing to long-term immune response against cancer. Additionally, our investigations into the impact of C202 on the tumor microenvironment found that it enhanced the anti-tumor response of both innate and adaptive immune systems, bolstering the immune-mediated fight against tumors. Furthermore, we made an intriguing observation regarding C202's synergistic effects. It was found to enhance the anti-tumor activity of chemotherapy drug gemcitabine and the angiogenesis inhibitor AL3810, which provide potential combination therapies in future translational studies.ConclusionsOur research highlights C202 as a novel STING agonist with durable anti-tumor activity that can be administered orally, presenting a promising candidate for cancer immunotherapy. C202 specifically activates various STING isoforms and its downstream signalling, and exhibited high oral bioavailability and plasma exposure and displayed broad-spectrum anti-tumor activity either by local or oral administration. C202 activated both innate and adaptive anti-tumor immunity, and importantly it induced complete tumor regression and immune memory,C202 exerts synergistic effects with chemotherapy (gemcitabine) or angiogenesis inhibitor (AL3810) in anti-tumor. # image

Polymeric STING Pro-agonists for Tumor-Specific Sonodynamic Immunotherapy.

Sono-Driven STING Activation Using Semiconducting Polymeric Nanoagonists for Precision Sono-Immunotherapy of Head and Neck Squamous Cell Carcinoma

Albumin-based co-loaded sonosensitizer and STING agonist nanodelivery system for enhanced sonodynamic and immune combination antitumor therapy

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Multifunctional Mesoporous Polydopamine‐Based Systematic Delivery of STING Agonist for Enhanced Synergistic Photothermal‐Immunotherapy

A novel STING agonist with systemic and durable anti-tumour activity

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

Bioactivable Sting Nanoagonists to Synergize Nir‐Ii Mild Photothermal Therapy Primed Robust and Long‐Term Anticancer Immunity

A Type I Photosensitizer-Polymersome Boosts Reactive Oxygen Species Generation by Forcing H-Aggregation for Amplifying STING Immunotherapy

Engineered PLGA Microparticles for Long-Term, Pulsatile Release of STING Agonist for Cancer Immunotherapy

Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy

Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Activatable Semiconducting Polymer Pro-nanomodulators for Deep-Tissue Sono-immunotherapy of Orthotopic Pancreatic Cancer

A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy

STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy

Branched Polymer‐Based Redox/Enzyme‐Activatable Photodynamic Nanoagent to Trigger STING‐Dependent Immune Responses for Enhanced Therapeutic Effect

Activatable cancer sono‐immunotherapy using semiconducting polymer nanobodies

Immunogenic nanomedicine based on GSH-responsive nanoscale covalent organic polymers for chemo-sonodynamic therapy

Mn-phenolic networks as synergistic carrier for STING agonists in tumor immunotherapy